Exelixis, Inc. (EXEL)
Price:
44.75 USD
( - -0.39 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
Incyte Corporation
VALUE SCORE:
10
2nd position
ADMA Biologics, Inc.
VALUE SCORE:
11
The best
Harmony Biosciences Holdings, Inc.
VALUE SCORE:
12
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
DESCRIPTION
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
NEWS
Here's Why Exelixis (EXEL) is a Strong Momentum Stock
zacks.com
2026-02-24 10:50:37Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Exelixis (NASDAQ:EXEL) EVP Dana Aftab Sells 29,873 Shares of Stock
defenseworld.net
2026-02-24 04:48:54Exelixis, Inc. (NASDAQ: EXEL - Get Free Report) EVP Dana Aftab sold 29,873 shares of the stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $44.35, for a total transaction of $1,324,867.55. Following the completion of the transaction, the executive vice president owned 664,024 shares in
Exelixis, Inc. $EXEL Shares Bought by Hillsdale Investment Management Inc.
defenseworld.net
2026-02-23 06:10:45Hillsdale Investment Management Inc. grew its holdings in Exelixis, Inc. (NASDAQ: EXEL) by 22.2% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 100,600 shares of the biotechnology company's stock after buying an additional 18,300 shares during the period. Hillsdale Investment Management Inc.'s
Exelixis: The Cash‑Generating Biotech That I Think Deserves a Closer Look in 2026
fool.com
2026-02-20 15:45:00Exelixis' main franchise has helped it perform well in recent years. The biotech company is developing new, promising cancer drugs.
Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term
zacks.com
2026-02-20 10:46:09The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Bob Oliver Sells 30,250 Shares of Exelixis (NASDAQ:EXEL) Stock
defenseworld.net
2026-02-20 06:50:49Exelixis, Inc. (NASDAQ: EXEL - Get Free Report) Director Bob Oliver sold 30,250 shares of the firm's stock in a transaction on Friday, February 13th. The stock was sold at an average price of $43.81, for a total transaction of $1,325,252.50. Following the completion of the sale, the director owned 21,120 shares of the company's stock,
Christopher Senner Sells 34,278 Shares of Exelixis (NASDAQ:EXEL) Stock
defenseworld.net
2026-02-20 06:50:49Exelixis, Inc. (NASDAQ: EXEL - Get Free Report) CFO Christopher Senner sold 34,278 shares of the business's stock in a transaction that occurred on Friday, February 13th. The shares were sold at an average price of $43.00, for a total value of $1,473,954.00. Following the completion of the sale, the chief financial officer owned 1,042,579 shares
Christopher Senner Sells 30,617 Shares of Exelixis (NASDAQ:EXEL) Stock
defenseworld.net
2026-02-20 06:50:47Exelixis, Inc. (NASDAQ: EXEL - Get Free Report) CFO Christopher Senner sold 30,617 shares of the firm's stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $43.67, for a total value of $1,337,044.39. Following the completion of the transaction, the chief financial officer owned 976,092 shares of the
Brenda Hefti Sells 18,669 Shares of Exelixis (NASDAQ:EXEL) Stock
defenseworld.net
2026-02-20 06:06:58Exelixis, Inc. (NASDAQ: EXEL - Get Free Report) SVP Brenda Hefti sold 18,669 shares of the firm's stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $44.01, for a total transaction of $821,622.69. Following the completion of the transaction, the senior vice president directly owned 96,512 shares in
A Dive into Exelixis (EXEL) International Revenue Trends and Forecasts
zacks.com
2026-02-16 10:16:18Review Exelixis' (EXEL) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
Illinois Municipal Retirement Fund Boosts Position in Exelixis, Inc. $EXEL
defenseworld.net
2026-02-14 04:30:49Illinois Municipal Retirement Fund grew its holdings in shares of Exelixis, Inc. (NASDAQ: EXEL) by 19.1% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 204,211 shares of the biotechnology company's stock after buying an additional 32,737 shares during the
Here's Why Exelixis (EXEL) is a Strong Value Stock
zacks.com
2026-02-13 10:41:03Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
EXEL or LQDA: Which Is the Better Value Stock Right Now?
zacks.com
2026-02-12 12:41:08Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Exelixis (EXEL) or Liquidia Corporation (LQDA). But which of these two stocks offers value investors a better bang for their buck right now?
Exelixis Reports Solid Earnings—Are New Highs Back on the Table?
marketbeat.com
2026-02-12 12:40:23Exelixis Inc. NASDAQ: EXEL stock is down about 2% in early trading the day after the company delivered a solid, but mixed earnings report. The company reported earnings per share (EPS) of 94 cents, which was 27% above the consensus estimate and 95% higher on a year-over-year (YoY) basis.
EXEL Q4 Earnings and Revenues Beat, Colorectal Cancer Drug in Focus
zacks.com
2026-02-11 11:02:23Exelixis tops Q4 estimates with new buybacks boosting momentum. Cabometyx sales climb and zanzalintinib advances toward FDA review.
Exelixis, Inc. (EXEL) Q4 2025 Earnings Call Transcript
seekingalpha.com
2026-02-10 20:54:20Exelixis, Inc. (EXEL) Q4 2025 Earnings Call Transcript
No data to display
Here's Why Exelixis (EXEL) is a Strong Momentum Stock
zacks.com
2026-02-24 10:50:37Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Exelixis (NASDAQ:EXEL) EVP Dana Aftab Sells 29,873 Shares of Stock
defenseworld.net
2026-02-24 04:48:54Exelixis, Inc. (NASDAQ: EXEL - Get Free Report) EVP Dana Aftab sold 29,873 shares of the stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $44.35, for a total transaction of $1,324,867.55. Following the completion of the transaction, the executive vice president owned 664,024 shares in
Exelixis, Inc. $EXEL Shares Bought by Hillsdale Investment Management Inc.
defenseworld.net
2026-02-23 06:10:45Hillsdale Investment Management Inc. grew its holdings in Exelixis, Inc. (NASDAQ: EXEL) by 22.2% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 100,600 shares of the biotechnology company's stock after buying an additional 18,300 shares during the period. Hillsdale Investment Management Inc.'s
Exelixis: The Cash‑Generating Biotech That I Think Deserves a Closer Look in 2026
fool.com
2026-02-20 15:45:00Exelixis' main franchise has helped it perform well in recent years. The biotech company is developing new, promising cancer drugs.
Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term
zacks.com
2026-02-20 10:46:09The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Bob Oliver Sells 30,250 Shares of Exelixis (NASDAQ:EXEL) Stock
defenseworld.net
2026-02-20 06:50:49Exelixis, Inc. (NASDAQ: EXEL - Get Free Report) Director Bob Oliver sold 30,250 shares of the firm's stock in a transaction on Friday, February 13th. The stock was sold at an average price of $43.81, for a total transaction of $1,325,252.50. Following the completion of the sale, the director owned 21,120 shares of the company's stock,
Christopher Senner Sells 34,278 Shares of Exelixis (NASDAQ:EXEL) Stock
defenseworld.net
2026-02-20 06:50:49Exelixis, Inc. (NASDAQ: EXEL - Get Free Report) CFO Christopher Senner sold 34,278 shares of the business's stock in a transaction that occurred on Friday, February 13th. The shares were sold at an average price of $43.00, for a total value of $1,473,954.00. Following the completion of the sale, the chief financial officer owned 1,042,579 shares
Christopher Senner Sells 30,617 Shares of Exelixis (NASDAQ:EXEL) Stock
defenseworld.net
2026-02-20 06:50:47Exelixis, Inc. (NASDAQ: EXEL - Get Free Report) CFO Christopher Senner sold 30,617 shares of the firm's stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $43.67, for a total value of $1,337,044.39. Following the completion of the transaction, the chief financial officer owned 976,092 shares of the
Brenda Hefti Sells 18,669 Shares of Exelixis (NASDAQ:EXEL) Stock
defenseworld.net
2026-02-20 06:06:58Exelixis, Inc. (NASDAQ: EXEL - Get Free Report) SVP Brenda Hefti sold 18,669 shares of the firm's stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $44.01, for a total transaction of $821,622.69. Following the completion of the transaction, the senior vice president directly owned 96,512 shares in
A Dive into Exelixis (EXEL) International Revenue Trends and Forecasts
zacks.com
2026-02-16 10:16:18Review Exelixis' (EXEL) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
Illinois Municipal Retirement Fund Boosts Position in Exelixis, Inc. $EXEL
defenseworld.net
2026-02-14 04:30:49Illinois Municipal Retirement Fund grew its holdings in shares of Exelixis, Inc. (NASDAQ: EXEL) by 19.1% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 204,211 shares of the biotechnology company's stock after buying an additional 32,737 shares during the
Here's Why Exelixis (EXEL) is a Strong Value Stock
zacks.com
2026-02-13 10:41:03Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
EXEL or LQDA: Which Is the Better Value Stock Right Now?
zacks.com
2026-02-12 12:41:08Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Exelixis (EXEL) or Liquidia Corporation (LQDA). But which of these two stocks offers value investors a better bang for their buck right now?
Exelixis Reports Solid Earnings—Are New Highs Back on the Table?
marketbeat.com
2026-02-12 12:40:23Exelixis Inc. NASDAQ: EXEL stock is down about 2% in early trading the day after the company delivered a solid, but mixed earnings report. The company reported earnings per share (EPS) of 94 cents, which was 27% above the consensus estimate and 95% higher on a year-over-year (YoY) basis.
EXEL Q4 Earnings and Revenues Beat, Colorectal Cancer Drug in Focus
zacks.com
2026-02-11 11:02:23Exelixis tops Q4 estimates with new buybacks boosting momentum. Cabometyx sales climb and zanzalintinib advances toward FDA review.
Exelixis, Inc. (EXEL) Q4 2025 Earnings Call Transcript
seekingalpha.com
2026-02-10 20:54:20Exelixis, Inc. (EXEL) Q4 2025 Earnings Call Transcript